PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS

May 1, 2011, 00:00 AM
10.1016/j.jval.2011.02.1061
https://www.valueinhealthjournal.com/article/S1098-3015(11)01200-9/fulltext
Section Title : Disease-Specific Studies
Section Order : 546
First Page : A192
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)01200-9&doi=10.1016/j.jval.2011.02.1061
HEOR Topics :
Tags :
Regions :